1-(2-溴乙氧基)-3-氯苯 | 6487-84-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 1-(2-溴乙氧基)-3-氯苯
• 中文别名: 颜料黄3；2-[(4-氯-2-硝基苯基)偶氮]-N-(2-氯苯基)-3-氧代-丁酰胺
• 英文名称: 2-bromoethyl 3-chlorophenyl ether
• 英文别名: 1-(2-bromo-ethoxy)-3-chloro-benzene；2-(3-Chlor-phenoxy)-ethylbromid；1-(2-Bromoethoxy)-3-chlorobenzene
• CAS: 6487-84-9
• 化学式: C₈H₈BrClO
• mdl: MFCD02030630
• 分子量: 235.508
• InChiKey: FUQNMWDFNCBVOK-UHFFFAOYSA-N

物化性质

• 沸点：
  142-147 °C (17.5 mmHg)
• 闪点：
  150 °C
• 稳定性/保质期：
  避免与不相容材料接触，尤其是强氧化剂。

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn,Xi
• 海关编码：
  2909309090
• 储存条件：
  密封储存，应存放在阴凉、干燥的库房中。

SDS

Name:	1-(2-Bromoethoxy)-3-chlorobenzene Material Safety Data Sheet
Synonym:
CAS:	6487-84-9

Section 1 - Chemical Product MSDS Name:1-(2-Bromoethoxy)-3-chlorobenzene Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
6487-84-9	1-(2-Bromoethoxy)-3-chlorobenzene		unlisted

Hazard Symbols: XN
Risk Phrases: 20/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation and if swallowed. Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 6487-84-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: colorless
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 142 - 147 deg C @17.5mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: 150 deg C ( 302.00 deg F)
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: >150 deg C
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H8BrClO
Molecular Weight: 235.51

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, carbon monoxide, carbon dioxide, hydrogen bromide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 6487-84-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-(2-Bromoethoxy)-3-chlorobenzene - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2810
Packing Group: III
IMO
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2810
Packing Group: III
RID/ADR
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2810
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/22 Harmful by inhalation and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 6487-84-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 6487-84-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 6487-84-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(2-溴乙氧基)-3-氯苯 在 18-冠醚-6 、 甲胺 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 2-(3-氯苯氧基)乙胺
  参考文献：
  名称：

  发现新型pERK1 / 2或β-arrestin偏爱的5-HT1A受体偏向激动剂：多种治疗样与副作用的关系。

  摘要：

  获得了对5-羟色胺5-HT 1A受体具有高亲和力和选择性的新型1-（1-苯甲酰基哌啶丁-4-基）甲胺衍生物，并在四种功能测定中进行了测试：ERK1 / 2磷酸化，腺苷酸环化酶抑制，钙动员和β-抑制蛋白的募集。选择化合物44和56（分别为2-甲基氨基苯氧基乙基和2-（1 H-吲哚-4-基氧基）乙基衍生物）作为具有高度差异性的“信号指纹”的偏向激动剂，这些信号被翻译成不同的体内特征。在体外，44显示出对ERK1 / 2磷酸化的偏向激动作用，而在体内，它在大鼠Porsolt强迫游泳试验中优先发挥了抗抑郁样作用。相反，化合物56表现出一流的特性：它在体外优先有效地激活β-arrestin募集，并在体内有效引起下唇缩回，这是“ 5-羟色胺能综合症”的一个组成部分。两种化合物均显示出良好的可显影性。提出的5-HT 1A受体偏向激动剂，优先针对各种信号传导途径，有可能成为独特的中枢神经系统病理学的候选药

  DOI：

  10.1021/acs.jmedchem.0c00814
• 作为产物：
  描述：

  3-氯苯酚 、 1,2-二溴乙烷 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 48.0h， 以35%的产率得到1-(2-溴乙氧基)-3-氯苯
  参考文献：
  名称：

  发现新型pERK1 / 2或β-arrestin偏爱的5-HT1A受体偏向激动剂：多种治疗样与副作用的关系。

  摘要：

  获得了对5-羟色胺5-HT 1A受体具有高亲和力和选择性的新型1-（1-苯甲酰基哌啶丁-4-基）甲胺衍生物，并在四种功能测定中进行了测试：ERK1 / 2磷酸化，腺苷酸环化酶抑制，钙动员和β-抑制蛋白的募集。选择化合物44和56（分别为2-甲基氨基苯氧基乙基和2-（1 H-吲哚-4-基氧基）乙基衍生物）作为具有高度差异性的“信号指纹”的偏向激动剂，这些信号被翻译成不同的体内特征。在体外，44显示出对ERK1 / 2磷酸化的偏向激动作用，而在体内，它在大鼠Porsolt强迫游泳试验中优先发挥了抗抑郁样作用。相反，化合物56表现出一流的特性：它在体外优先有效地激活β-arrestin募集，并在体内有效引起下唇缩回，这是“ 5-羟色胺能综合症”的一个组成部分。两种化合物均显示出良好的可显影性。提出的5-HT 1A受体偏向激动剂，优先针对各种信号传导途径，有可能成为独特的中枢神经系统病理学的候选药

  DOI：

  10.1021/acs.jmedchem.0c00814

文献信息

• Targeting the Binding Function 3 (BF3) Site of the Androgen Receptor Through Virtual Screening. 2. Development of 2-((2-phenoxyethyl) thio)-1<i>H</i>-benzimidazole Derivatives
  作者：Ravi Shashi Nayana Munuganti、Eric Leblanc、Peter Axerio-Cilies、Christophe Labriere、Kate Frewin、Kriti Singh、Mohamed D. H. Hassona、Nathan A. Lack、Huifang Li、Fuqiang Ban、Emma Tomlinson Guns、Robert Young、Paul S. Rennie、Artem Cherkasov

  DOI：10.1021/jm3015712

  日期：2013.2.14

  The human androgen receptor (AR) is a proven therapeutic target in prostate cancer. All current antiandrogens, such as Bicalutamide, Flutamide, Nilutamide, and Enzalutamide, target the buried hydrophobic androgen binding pocket of this protein. However, effective resistance mechanisms against these therapeutics exist such as mutations occurring at the target site. To overcome these limitations, the

  人类雄激素受体（AR）是前列腺癌中公认的治疗靶标。当前所有的抗雄激素药，例如比卡鲁胺，氟他米特，尼鲁米特和恩杂鲁米特，都靶向该蛋白的隐埋的疏水性雄激素结合袋。然而，存在对这些治疗剂的有效抗性机制，例如在靶位点发生的突变。为了克服这些限制，AR的称为结合功能3（BF3）的表面囊被表征为小分子治疗剂的替代靶标。许多AR抑制剂直接靶向BF3的先前由我们（标识药物化学杂志。 2011。54，8563）。在当前的研究中，基于先前的结果，我们开发了结构-活性关系，从而可以设计一系列2-（（2-苯氧基乙基）硫基）-1 H-苯并咪唑和2-（（2-苯氧基乙基）硫基） -1 H-吲哚作为铅BF3抑制剂。一些已开发的BF3配体对LNCaP和耐恩杂鲁胺的前列腺癌细胞系表现出显着的抗雄激素作用。
• Prostaglandin agonists and their use to treat bone disorders
  申请人：Pfizer Inc.

  公开号：US06498172B1

  公开（公告）日：2002-12-24

  This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.

  本发明涉及前列腺素受体激动剂、使用此类前列腺素受体激动剂的方法、含有此类前列腺素受体激动剂的药物组合物以及含有此类前列腺素受体激动剂的试剂盒。这些前列腺素受体激动剂可用于治疗包括骨质疏松症在内的骨骼疾病。
• Methods of treatment using an EP2 selective receptor agonist
  申请人：Constan A. Alexander

  公开号：US20050203086A1

  公开（公告）日：2005-09-15

  The present invention relates to methods of treating pulmonary hypertension, facilitating joint fusion, facilitating tendon and ligament repair, reducing the occurrence of secondary fracture, treating avascular necrosis, facilitating cartilage repair, facilitating bone healing after limb transplantation, facilitating liver regeneration, facilitating wound healing, reducing the occurrence of gastric ulceration, treating hypertension, facilitating the growth of tooth enamel or finger or toe nails, treating glaucoma, treating ocular hypertension, and repairing damage caused by metastatic bone disease using an EP 2 selective receptor agonist.

  本发明涉及使用EP2选择性受体激动剂治疗肺动脉高压、促进关节融合、促进肌腱和韧带修复、减少继发性骨折的发生、治疗缺血性坏死、促进软骨修复、促进肢体移植后的骨愈合、促进肝脏再生、促进伤口愈合、减少胃溃疡的发生、治疗高血压、促进牙齿珐琅质或手指甲和脚趾甲的生长、治疗青光眼、治疗眼高压以及修复由转移性骨疾病引起的损伤的方法。
• [EN] DOPAMINE D2 RECEPTOR LIGANDS<br/>[FR] LIGANDS DES RÉCEPTEURS DOPAMINERGIQUES D2
  申请人：BROAD INST INC

  公开号：WO2016100940A1

  公开（公告）日：2016-06-23

  The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity. The present invention relates to novel compounds that modulate dopamine D2 receptors. In particular, compounds of the present invention show functional selectivity at the dopamine D2 receptors and exhibit selectivity downstream of the D2 receptors, on the 0- arrestin pathway and/or on the cAMP pathway.

  本发明涉及新型多巴胺D2受体配体。该发明进一步涉及功能偏向的多巴胺D2受体配体以及利用这些化合物治疗或预防与多巴胺活性失调相关的中枢神经系统和全身性疾病。本发明涉及调节多巴胺D2受体的新型化合物。具体而言，本发明的化合物在多巴胺D2受体上显示功能选择性，并在D2受体下游、0-阿雷斯汀途径和/或cAMP途径上表现出选择性。
• Tetrahydrofuran-Based Transient Receptor Potential Ankyrin 1 (TRPA1) Antagonists: Ligand-Based Discovery, Activity in a Rodent Asthma Model, and Mechanism-of-Action via Cryogenic Electron Microscopy
  作者：Jack A. Terrett、Huifen Chen、Daniel G. Shore、Elisia Villemure、Robin Larouche-Gauthier、Martin Déry、Francis Beaumier、Léa Constantineau-Forget、Chantal Grand-Maître、Luce Lépissier、Stéphane Ciblat、Claudio Sturino、Yong Chen、Baihua Hu、Aijun Lu、Yunli Wang、Andrew P. Cridland、Stuart I. Ward、David H. Hackos、Rebecca M. Reese、Shannon D. Shields、Jun Chen、Alessia Balestrini、Lorena Riol-Blanco、Wyne P. Lee、John Liu、Eric Suto、Xiumin Wu、Juan Zhang、Justin Q. Ly、Hank La、Kevin Johnson、Matt Baumgardner、Kang-Jye Chou、Alexis Rohou、Lionel Rougé、Brian S. Safina、Steven Magnuson、Matthew Volgraf

  DOI：10.1021/acs.jmedchem.0c02023

  日期：2021.4.8

  ankyrin 1 (TRPA1) is a nonselective calcium-permeable ion channel highly expressed in the primary sensory neurons functioning as a polymodal sensor for exogenous and endogenous stimuli and has generated widespread interest as a target for inhibition due to its implication in neuropathic pain and respiratory disease. Herein, we describe the optimization of a series of potent, selective, and orally bioavailable

  瞬时受体电位锚蛋白 1 (TRPA1) 是一种非选择性钙渗透性离子通道，在初级感觉神经元中高度表达，充当外源性和内源性刺激的多模式传感器，由于其在神经性疼痛中的作用，作为抑制靶点引起了广泛的兴趣和呼吸道疾病。在此，我们描述了一系列有效的、选择性的、口服生物可利用的 TRPA1 小分子拮抗剂的优化，从而发现了一种新型的基于四氢呋喃的接头。鉴于理化性质的平衡和大鼠 AITC 诱导的疼痛测定中强大的体内靶点参与，化合物20被进展到豚鼠卵清蛋白哮喘模型中，在该模型中它表现出显着的剂量依赖性炎症反应减少。此外，通过低温电子显微镜以3 Å的分辨率确定了与化合物21结合的TRPA1通道的结构，揭示了此类拮抗剂的结合位点和作用机制。